DDInter1746 DDInter1376
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tapentadol {u} (Compound) resembles {v} (Compound) Metaraminol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Tapentadol {u} (Compound) binds {v} (Gene) HTR3A
Tapentadol {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Agonists
Tapentadol {u} (Compound) causes {v} (Side Effect) Panic attack
Tapentadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propantheline
Tapentadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Tapentadol {u} may lead to a major life threatening interaction when taken with {v} Procarbazine
Tapentadol {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Tapentadol {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylephrine
Tapentadol (Compound) resembles Metaraminol (Compound)
Tapentadol (Compound) resembles Rivastigmine (Compound)
Tapentadol (Compound) binds HTR3A (Gene)
Tapentadol (Compound) is included by Opioid Agonists (Pharmacologic Class)
Tapentadol (Compound) causes Panic attack (Side Effect)
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Tapentadol may lead to a major life threatening interaction when taken with Procarbazine
Tapentadol may lead to a major life threatening interaction when taken with Methylene blue
Tapentadol (Compound) resembles Phenylephrine (Compound) and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine